1.25
price up icon3.31%   0.04
 
loading
전일 마감가:
$1.21
열려 있는:
$1.22
하루 거래량:
6,572
Relative Volume:
0.04
시가총액:
$45.72M
수익:
-
순이익/손실:
$-9.16M
주가수익비율:
-2.193
EPS:
-0.57
순현금흐름:
$-8.75M
1주 성능:
+0.00%
1개월 성능:
-8.09%
6개월 성능:
-7.41%
1년 성능:
+1.63%
1일 변동 폭
Value
$1.22
$1.25
1주일 범위
Value
$1.20
$1.275
52주 변동 폭
Value
$0.75
$1.6899

Renovorx Inc Stock (RNXT) Company Profile

Name
명칭
Renovorx Inc
Name
전화
408-800-2649
Name
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Name
직원
10
Name
트위터
Name
다음 수익 날짜
2024-08-15
Name
최신 SEC 제출 서류
Name
RNXT's Discussions on Twitter

RNXT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RNXT
Renovorx Inc
1.25 45.35M 0 -9.16M -8.75M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.92 118.67B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.64 59.23B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
408.98 52.67B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
677.23 41.24B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.30 32.36B 3.81B -644.79M -669.77M -6.24

Renovorx Inc 주식(RNXT)의 최신 뉴스

pulisher
03:08 AM

Is RenovoRx Inc. a growth stock or a value stockBreakthrough capital growth - jammulinksnews.com

03:08 AM
pulisher
Aug 03, 2025

What analysts say about RenovoRx Inc. stockUnlock powerful trading alerts for success - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What is RenovoRx Inc. company’s growth strategyHigh-octane financial growth - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Published on: 2025-08-04 04:04:54 - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is RenovoRx Inc. stock compared to the marketGet timely market insights for better trades - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for RenovoRx Inc. in the next 12 monthsUnlock steady growth with low-risk stocks - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

How does RenovoRx Inc. generate profit in a changing economyAccelerated profit realization - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are RenovoRx Inc. company’s key revenue driversGet daily expert analysis on top stocks - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about RenovoRx Inc.Breakneck growth rates - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Is RenovoRx Inc. stock overvalued or undervaluedAchieve rapid portfolio appreciation today - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What makes RenovoRx Inc. stock price move sharplyAchieve superior returns through strategic trading - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What drives RenovoRx Inc. stock priceOutstanding stock performance - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

When is RenovoRx Inc. stock expected to show significant growthUnlock market-leading stock analysis - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 02, 2025

Should I hold or sell RenovoRx Inc. stock in 2025Outstanding stock performance - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What catalysts could drive RenovoRx Inc. stock higher in 2025Accelerated investment success - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What institutional investors are buying RenovoRx Inc. stockUnlock powerful trading alerts for success - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

RenovoRx (NASDAQ:RNXT) Rating Lowered to Sell at Wall Street Zen - Defense World

Aug 02, 2025
pulisher
Aug 01, 2025

Exit strategy if you’re trapped in RenovoRx Inc.Swing Trade Entry and Exit Point Analysis - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

Will RenovoRx Inc. price bounce be sustainableFree Capital Growth With Controlled Risk Picks - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

Why RenovoRx Inc. stock attracts strong analyst attentionDaily Market Momentum and Pressure Analysis - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Will RenovoRx Inc. stock recover after recent dropMinimal Risk Growth Investment Opportunity Analysis - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Can you recover from losses in RenovoRx Inc.Short-Term Stock Trend Forecast Guide - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

How RenovoRx Inc. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings Preview For RenovoRx - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

Can swing trading help recover from RenovoRx Inc. lossesDaily Equity Signal Strength Summary Report - Newser

Jul 31, 2025
pulisher
Jul 30, 2025

RenovoRx Inc. stock prediction for this weekFree Short Term High Yield Stock Tips - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

New Product Launches: Will They Boost RenovoRx Inc. Stock in 2025Fast Entry High Potential Stock Alerts Triggered - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Heatmap analysis for RenovoRx Inc. and competitorsBuy Signal System Based on Price Action - Newser

Jul 30, 2025
pulisher
Jul 29, 2025

Moving Average Trends for RenovoRx Inc. Stock: What They IndicateShort-Term Stock Trend Forecast Guide - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Ellis Martin Report: Redefining Cancer TreatmentRenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy - ABN Newswire

Jul 29, 2025
pulisher
Jul 29, 2025

RenovoRx launches multi-centre post-marketing registry study - European Pharmaceutical Manufacturer

Jul 29, 2025
pulisher
Jul 29, 2025

RenovoRx Inc. Moves Into Bullish Territory Based on MACDLow Risk High Return Opportunities Identified - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Is this a good reentry point in RenovoRx Inc.Oversold Stock Bounce Playbook Generator - Newser

Jul 29, 2025
pulisher
Jul 28, 2025

Pancreatic Ductal Adenocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix - Barchart.com

Jul 28, 2025
pulisher
Jul 28, 2025

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - BioSpace

Jul 28, 2025
pulisher
Jul 28, 2025

RenovoRx launches post-marketing study to advance real-world use of RenovoCath Device - Medical Economics

Jul 28, 2025
pulisher
Jul 28, 2025

RenovoRx to launch post-marketing registry study for cancer device By Investing.com - Investing.com Nigeria

Jul 28, 2025

Renovorx Inc (RNXT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$76.35
price up icon 0.54%
$37.71
price up icon 0.93%
$109.11
price up icon 0.45%
$27.20
price up icon 0.39%
$114.10
price up icon 5.16%
biotechnology ONC
$301.02
price down icon 0.05%
자본화:     |  볼륨(24시간):